RPSA and prion disease: Da Costa Dias et al. (2013) found that RPSA co-localizes with Aβ42 on the cell surface, and can physically bind to peptides that synthesize Aβ42, and low activity of RPSA can lead to enhanced Aβ42 toxicity. Research on targeting RPSA for prion diseases has been reported (Jovanovic et al., 2015), and the development of RPSA-targeted drugs can provide a new perspective for the treatment of AD.